{"id":"ctc-501","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CTC-501 is a monoclonal antibody that targets the CD47-SIRPα axis, a pathway that is often exploited by cancer cells to evade immune detection. By blocking this interaction, CTC-501 aims to restore the immune system's ability to recognize and attack cancer cells. This mechanism is thought to be particularly effective in the treatment of hematologic malignancies.","oneSentence":"CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:52.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT03642964","phase":"PHASE2","title":"A Study in Patients With Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chase Therapeutics Corporation","startDate":"2018-09-10","conditions":"Major Depressive Disorder (MDD)","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CTC-501","genericName":"CTC-501","companyName":"Chase Therapeutics Corporation","companyId":"chase-therapeutics-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CTC-501 is a CD47-SIRPα inhibitor, which works by blocking the interaction between CD47 and SIRPα on the surface of immune cells, thereby enhancing the immune system's ability to recognize and destroy cancer cells. Used for Relapsed or refractory acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}